The Endocrine Society recommended that physicians discuss the potential of cardiovascular risks with middle-age and older patients who are considering testosterone therapy to treat symptoms of declining testosterone levels.

Boston Scientific (NYSE: BSX) has announced the U.S. launch and first use of the OffRoad™ Re-Entry Catheter System, an important addition to the company's portfolio of tools to treat complete arterial blockages in the major arteries of the legs.  These blockages, called chronic total occlusions (CTOs), are associated with advanced peripheral artery disease (PAD).  The first use of the OffRoad System was performed by J.A. Mustapha, M.D., director of Cardiac Catheterization Laboratories, director of Endovascular Interventions, and director of Cardiovascular Research at Metro Health Hospital in Wyoming, Mich.

eCardio Diagnostics, a leader in remote arrhythmia monitoring services, today announced the opening of its second Independent Diagnostic Testing Facility (IDTF) in San Francisco, California.

The AstraZeneca HealthCare Foundation’s Connections for Cardiovascular HealthSM program today announced a grant of $197,634 to Saint Agnes Hospital Foundation to support its Heart-to-Heart initiative. This is the second consecutive year in which the Saint Agnes Hospital Foundation has received a grant from the AstraZeneca HealthCare Foundation, totaling $442,089.

The AstraZeneca HealthCare Foundation’s Connections for Cardiovascular HealthSM program today announced a grant of $213,094 to Christiana Care Health System to support its No Heart Left Behind program. This is the third consecutive year in which Christiana Care has received a grant from the AstraZeneca HealthCare Foundation, totaling $561,557.

This February during American Heart Month, Vivek Reddy, MD, of Mount Sinai Heart at The Mount Sinai Hospital implanted the United States' first miniature-sized, leadless cardiac pacemaker directly inside a patient's heart without surgery.

Edwards Lifesciences Corporation (NYSE: EW), the global leader in the science of heart valves and hemodynamic monitoring, today announced it has received CE Mark in Europe for valve-in-valve procedures using the SAPIEN XT transcatheter heart valve, providing a minimally invasive treatment option for patients whose surgical mitral or aortic valves require replacement, and who are at extreme risk for surgery. Edwards is the only company to receive a valve-in-valve indication for the mitral position, which addresses an unmet need within the clinical community to provide an alternative to a high-risk surgery.

Neovasc Inc. (TSXV: NVC) today announced that a first-in-human implantation of its Tiara™ transcatheter mitral valve was successfully performed on January 30th  by physicians at St. Paul’s Hospital in Vancouver, BC. The transapical procedure resulted in the elimination of mitral regurgitation (MR) and significantly improved heart function in the patient, without the need for cardiac bypass support and with no procedural complications.